A retrospective analysis on anti-CD20 antibody–treated Epstein–Barr virus–related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation
Abstract Posttransplantation lymphoproliferation disorder (PTLD) is a life-threatening complication after hematopoietic stem cell transplantation (HSCT). Anti-CD20 antibody is the most widely used antibody to eliminate infected B cells. Few studies have focused on prognostic factors predicting the outcome of EBV (Epstein–Barr virus)-PTLD. We conducted a retrospective analysis of 2571 haplo-HSCTs performed between 2010 and 2017 at the Peking University Institute of Hematology; seventy patients who had been treated with rituximab for PTLD were enrolled. The overall EBV-related PTLD frequency was 3.1%. With a median follow-up time of 365 days (range, 54–2659), the overall survival rate was 51.43% (36/70). The cumulative incidence of EBV-PTLD complete remission with anti-CD20 antibody monotherapy was 68.57% (48/70). EBV-PTLD-related mortality was 11.43% (8/70), while the transplantation-related mortality was 38.57% (27/70). Multivariate analysis showed that a decrease in EBV viral load 1 week after therapy was associated with high response rate of EBV-PTLD (p = 0.007, 0.106 (0.021–0.549)), low PTLD-related mortality (p = 0.010, HR 0.058 (0.007–0.503)), and transplantation-related mortality (p = 0.051, HR 0.441 (0.194–1.003)). For EBV-PTLD patients after haplo-HSCT who received rituximab as first-line therapy, non-decreased EBV viral load 1 week after anti-CD20 therapy could be high risk factor for poor outcomes..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:99 |
---|---|
Enthalten in: |
Annals of hematology - 99(2020), 11 vom: 24. März, Seite 2649-2657 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Luo, Xue-Yi [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: | |
---|---|
Themen: |
Epstein-Barr virus |
doi: |
10.1007/s00277-020-04003-8 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR041206673 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR041206673 | ||
003 | DE-627 | ||
005 | 20230520011744.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201102s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s00277-020-04003-8 |2 doi | |
035 | |a (DE-627)SPR041206673 | ||
035 | |a (SPR)s00277-020-04003-8-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
084 | |a 44.86 |2 bkl | ||
100 | 1 | |a Luo, Xue-Yi |e verfasserin |4 aut | |
245 | 1 | 2 | |a A retrospective analysis on anti-CD20 antibody–treated Epstein–Barr virus–related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract Posttransplantation lymphoproliferation disorder (PTLD) is a life-threatening complication after hematopoietic stem cell transplantation (HSCT). Anti-CD20 antibody is the most widely used antibody to eliminate infected B cells. Few studies have focused on prognostic factors predicting the outcome of EBV (Epstein–Barr virus)-PTLD. We conducted a retrospective analysis of 2571 haplo-HSCTs performed between 2010 and 2017 at the Peking University Institute of Hematology; seventy patients who had been treated with rituximab for PTLD were enrolled. The overall EBV-related PTLD frequency was 3.1%. With a median follow-up time of 365 days (range, 54–2659), the overall survival rate was 51.43% (36/70). The cumulative incidence of EBV-PTLD complete remission with anti-CD20 antibody monotherapy was 68.57% (48/70). EBV-PTLD-related mortality was 11.43% (8/70), while the transplantation-related mortality was 38.57% (27/70). Multivariate analysis showed that a decrease in EBV viral load 1 week after therapy was associated with high response rate of EBV-PTLD (p = 0.007, 0.106 (0.021–0.549)), low PTLD-related mortality (p = 0.010, HR 0.058 (0.007–0.503)), and transplantation-related mortality (p = 0.051, HR 0.441 (0.194–1.003)). For EBV-PTLD patients after haplo-HSCT who received rituximab as first-line therapy, non-decreased EBV viral load 1 week after anti-CD20 therapy could be high risk factor for poor outcomes. | ||
650 | 4 | |a Posttransplantation lymphoproliferation disorder |7 (dpeaa)DE-He213 | |
650 | 4 | |a Epstein-Barr virus |7 (dpeaa)DE-He213 | |
650 | 4 | |a Haplo identical hematopoietic stem cell transplantation |7 (dpeaa)DE-He213 | |
650 | 4 | |a Rituximab |7 (dpeaa)DE-He213 | |
650 | 4 | |a Risk factor analysis |7 (dpeaa)DE-He213 | |
700 | 1 | |a Mo, Xiao-Dong |e verfasserin |4 aut | |
700 | 1 | |a Xu, Lan-Ping |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Xiao-Hui |e verfasserin |4 aut | |
700 | 1 | |a Wang, Yu |e verfasserin |4 aut | |
700 | 1 | |a Liu, Kai-Yan |e verfasserin |4 aut | |
700 | 1 | |a Chang, Ying-Jun |e verfasserin |4 aut | |
700 | 1 | |a Zhao, Xiang-Yu |e verfasserin |4 aut | |
700 | 1 | |a Huang, Xiao-Jun |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Annals of hematology |d Berlin : Springer, 1955 |g 99(2020), 11 vom: 24. März, Seite 2649-2657 |w (DE-627)SPR003573435 |w (DE-600)1458429-3 |x 1432-0584 |7 nnns |
773 | 1 | 8 | |g volume:99 |g year:2020 |g number:11 |g day:24 |g month:03 |g pages:2649-2657 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00277-020-04003-8 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
936 | b | k | |a 44.86 |q ASE |
951 | |a AR | ||
952 | |d 99 |j 2020 |e 11 |b 24 |c 03 |h 2649-2657 |